198 related articles for article (PubMed ID: 36718061)
1. Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women.
Zhang X; Luo T; Yang H; Ma WY; He Q; Xu M; Yang Y
Curr Drug Metab; 2023; 23(14):1115-1123. PubMed ID: 36718061
[TBL] [Abstract][Full Text] [Related]
2. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
[TBL] [Abstract][Full Text] [Related]
4. Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.
Moss DM; Domanico P; Watkins M; Park S; Randolph R; Wring S; Rajoli RKR; Hobson J; Rannard S; Siccardi M; Owen A
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416547
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19.
Liu XI; Dallmann A; Brooks K; Best BM; Clarke DF; Mirochnick M; van den Anker JN; Capparelli EV; Momper JD
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):148-153. PubMed ID: 36479969
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes.
Yang Y; Zhang X; Wang Y; Xi H; Xu M; Zheng L
Front Pharmacol; 2024; 15():1342515. PubMed ID: 38756374
[TBL] [Abstract][Full Text] [Related]
8. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
9. Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.
Eke AC
J Pharm Drug Res; 2022; 5(1):585-593. PubMed ID: 35845086
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
11. PBPK/PD Modeling of Nifedipine for Precision Medicine in Pregnant Women: Enhancing Clinical Decision-Making for Optimal Drug Therapy.
Liu X; Wang W; Chen J; Chen D; Tao Y; Ouyang D
Pharm Res; 2024 Jan; 41(1):63-75. PubMed ID: 38049651
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.
Eke AC; Shoji K; Best BM; Momper JD; Stek AM; Cressey TR; Mirochnick M; Capparelli EV
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318014
[TBL] [Abstract][Full Text] [Related]
13. Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil.
Shen C; Liang D; Wang X; Shao W; Geng K; Wang X; Sun H; Xie H
Front Pharmacol; 2022; 13():1013432. PubMed ID: 36278167
[No Abstract] [Full Text] [Related]
14. Physiologically-based pharmacokinetics of ziprasidone in pregnant women.
Biesdorf C; Martins FS; Sy SKB; Diniz A
Br J Clin Pharmacol; 2019 May; 85(5):914-923. PubMed ID: 30669177
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF).
Thimm MA; Livingston A; Ramroop R; Eke AC
J AIDS HIV Treat; 2022; 4(1):6-13. PubMed ID: 35466327
[TBL] [Abstract][Full Text] [Related]
16. A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects.
Kim YK; Choi MJ; Oh TY; Yu KS; Lee S
Drug Des Devel Ther; 2017; 11():3171-3177. PubMed ID: 29158663
[TBL] [Abstract][Full Text] [Related]
17. Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations.
Jogiraju VK; Avvari S; Gollen R; Taft DR
Biopharm Drug Dispos; 2017 Oct; 38(7):426-438. PubMed ID: 28474821
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
20. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
